Lixte Biotech Hlds (LIXT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,251 | 5,107 | 2,888 | 887 | 1,385 |
| Other current assets | 0 | 0 | 2,455 | 0 | 0 |
| TOTAL | $3,408 | $5,178 | $5,434 | $990 | $1,514 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 7,458 | 7,555 | 0 | 199 | 0 |
| TOTAL | $7,458 | $7,555 | $N/A | $199 | $N/A |
| Total Assets | $10,865 | $12,734 | $5,434 | $1,189 | $1,514 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 391 | 437 | 236 | 92 | 113 |
| Accrued Expenses | N/A | N/A | N/A | 189 | N/A |
| Other current liabilities | 238 | 301 | 286 | 256 | 243 |
| TOTAL | $1,225 | $1,333 | $521 | $537 | $355 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 526 | 439 | 0 | 0 | 0 |
| TOTAL | $462 | $439 | $N/A | $N/A | $N/A |
| Total Liabilities | $1,687 | $1,772 | $521 | $537 | $355 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 12,383 | 11,618 | 5,704 | 4,561 | 2,684 |
| Common Shares | 1 | 1 | 1 | 0 | 0 |
| Retained earnings | -60,001 | -58,077 | -55,533 | -53,553 | -52,777 |
| Other shareholders' equity | 1,234 | 1,298 | 0 | 0 | 0 |
| TOTAL | $9,179 | $10,962 | $4,912 | $652 | $1,159 |
| Total Liabilities And Equity | $10,865 | $12,734 | $5,434 | $1,189 | $1,514 |